P18 is a tumor suppressor gene involved in human medullary thyroid carcinoma and pheochromocytoma development

In multiple endocrine neoplasia syndrome Type 2 (MEN2), medullary thyroid carcinoma (MTC) and pheochromocytoma (PC) are associated with hereditary activating germ‐line mutations in the RET proto‐oncogene. Also in a large percentage of sporadic MTCs and PCs, somatic RET mutations appear to be involved in tumor formation. In one single MEN2 family an extensive variety in disease expression may be observed, indicating that additional genetic events are responsible for progression of the disease towards a more aggressive phenotype. However, these additional mutations in both hereditary and sporadic MTC and PC development are largely unknown. Here, we show for the first time the presence of somatic mutations in the cell cycle regulator P18 in human RET‐associated MTCs and PCs. Each of these mutations causes an amino acid substitution in the cyclin dependent kinase‐interacting region of P18INK4C. Since these mutations partly inhibited P18INK4C function and reduced its stability, our findings implicate P18 as a tumor suppressor gene involved in human MTC and PC development. © 2008 Wiley‐Liss, Inc.

[1]  D. Franklin,et al.  Synergistic effect of oncogenic RET and loss of p18 on medullary thyroid carcinoma development. , 2008, Cancer research.

[2]  D. Franklin,et al.  Simultaneous downregulation of CDK inhibitors p18Ink4c and p27Kip1 is required for MEN2A-RET-mediated mitogenesis , 2007, Oncogene.

[3]  P. Pandolfi,et al.  p18Ink4c and Pten Constrain a Positive Regulatory Loop between Cell Growth and Cell Cycle Control , 2006, Molecular and Cellular Biology.

[4]  J. Cordier,et al.  Idiopathic chronic eosinophilic pneumonia , 2006, Orphanet journal of rare diseases.

[5]  F. Zindy,et al.  The CDK Inhibitor p18Ink4c is a Tumor Suppressor in Medulloblastoma , 2006, Cell cycle.

[6]  M. Hatten,et al.  The tumor suppressors Ink4c and p53 collaborate independently with Patched to suppress medulloblastoma formation. , 2005, Genes & development.

[7]  H. Yoshiji,et al.  Reduced expression of cell cycle regulator p18INK4C in human hepatocellular carcinoma , 2004, Hepatology.

[8]  Juan F. García,et al.  Silencing of the p18INK4c gene by promoter hypermethylation in Reed-Sternberg cells in Hodgkin lymphomas. , 2004, Blood.

[9]  A. Vettori,et al.  Fine analysis of the short arm of chromosome 1 in sporadic and familial pheochromocytoma , 2003, Clinical endocrinology.

[10]  D. Marsh,et al.  Genome-wide copy number imbalances identified in familial and sporadic medullary thyroid carcinoma. , 2003, The Journal of clinical endocrinology and metabolism.

[11]  V. Godfrey,et al.  Haploinsufficiency of p18INK4c Sensitizes Mice to Carcinogen-Induced Tumorigenesis , 2003, Molecular and Cellular Biology.

[12]  Ronen Marmorstein,et al.  Structure-based Design of p18INK4cProteins with Increased Thermodynamic Stability and Cell Cycle Inhibitory Activity* , 2002, The Journal of Biological Chemistry.

[13]  C. Larsson,et al.  Loss of Heterozygosity on the Short Arm of Chromosome 1 in Pheochromocytoma and Abdominal Paraganglioma , 2002, World Journal of Surgery.

[14]  V. P. Collins,et al.  Alterations of the tumor suppressor genes CDKN2A (p16(INK4a)), p14(ARF), CDKN2B (p15(INK4b)), and CDKN2C (p18(INK4c)) in atypical and anaplastic meningiomas. , 2001, The American journal of pathology.

[15]  B. Boehm,et al.  Genotype-phenotype correlations in hereditary medullary thyroid carcinoma: oncological features and biochemical properties. , 2001, The Journal of clinical endocrinology and metabolism.

[16]  K. Hoang-Xuan,et al.  P18 tumor suppressor gene and progression of oligodendrogliomas to anaplasia , 2000, Neurology.

[17]  V. Godfrey,et al.  Functional Collaboration between Different Cyclin-Dependent Kinase Inhibitors Suppresses Tumor Growth with Distinct Tissue Specificity , 2000, Molecular and Cellular Biology.

[18]  M. Tsai,et al.  Tumor suppressor INK4: quantitative structure-function analyses of p18INK4C as an inhibitor of cyclin-dependent kinase 4. , 2000, Biochemistry.

[19]  N. Skakkebaek,et al.  Cell cycle regulators in testicular cancer: Loss of p18INK4C marks progression from carcinoma in situ to invasive germ cell tumours , 2000, International journal of cancer.

[20]  M. Wolter,et al.  Identification of two distinct deleted regions on the short arm of chromosome 1 and rare mutation of the CDKN2C gene from 1p32 in oligodendroglial tumors. , 1999, Journal of neuropathology and experimental neurology.

[21]  W. Yarbrough,et al.  Biologic and biochemical analyses of p16(INK4a) mutations from primary tumors. , 1999, Journal of the National Cancer Institute.

[22]  M. Tsai,et al.  Tumor suppressor INK4: determination of the solution structure of p18INK4C and demonstration of the functional significance of loops in p18INK4C and p16INK4A. , 1999, Biochemistry.

[23]  Y. Xiong,et al.  Identification of functional elements of p18INK4C essential for binding and inhibition of cyclin-dependent kinase (CDK) 4 and CDK6. , 1999, Cancer research.

[24]  G. Peters,et al.  The p16INK4a/CDKN2A tumor suppressor and its relatives. , 1998, Biochimica et biophysica acta.

[25]  A. Blais,et al.  Structure of the gene encoding the human cyclin-dependent kinase inhibitor p18 and mutational analysis in breast cancer. , 1998, Biochemical and biophysical research communications.

[26]  K. Spirin,et al.  Analysis of p18INK4C in adult T‐cell leukaemia and non‐Hodgkin's lymphoma , 1997, British journal of haematology.

[27]  H. Koeffler,et al.  Molecular analysis of the INK4 family of genes in prostate carcinomas. , 1997, The Journal of urology.

[28]  R. Maestro,et al.  p16/CDKN2 and CDK4 gene mutations in sporadic melanoma development and progression , 1997, International journal of cancer.

[29]  J. Lapointe,et al.  A p18 mutant defective in CDK6 binding in human breast cancer cells. , 1996, Cancer research.

[30]  G. Peters,et al.  Temperature-sensitive mutants of p16CDKN2 associated with familial melanoma , 1996, Molecular and cellular biology.

[31]  T. Goodrow,et al.  Deletion and mutation analyses of the P16/MTS-1 tumor suppressor gene in human ductal pancreatic cancer reveals a higher frequency of abnormalities in tumor-derived cell lines than in primary ductal adenocarcinomas. , 1996, Cancer research.

[32]  P. Pollock,et al.  Compilation of somatic mutations of the CDKN2 gene in human cancers: Non‐random distribution of base substitutions , 1996, Genes, chromosomes & cancer.

[33]  C. Bartram,et al.  Molecular analysis of the cyclin‐dependent kinase inhibitor family: p16(CDKN2/MTS1/INK4A), p18(INK4C) and p27(Kip1) genes in neuroblastomas , 1996, Cancer.

[34]  H. Koeffler,et al.  Alterations of the p15, p16,and p18 genes in osteosarcoma. , 1996, Cancer genetics and cytogenetics.

[35]  Carl W. Miller,et al.  Molecular analysis of a family of cyclin‐dependent kinase inhibitor genes (p15/MTS2/INK4b and p18/INK4c) in non‐small cell lung cancers , 1995, Molecular carcinogenesis.

[36]  B. Ponder,et al.  Genotype‐phenotype correlation in multiple endocrine neoplasia type 2: report of the International RET Mutation Consortium , 1995, Journal of internal medicine.

[37]  C. Bartram,et al.  Analysis of a family of cyclin-dependent kinase inhibitors: p15/MTS2/INK4B, p16/MTS1/INK4A, and p18 genes in acute lymphoblastic leukemia of childhood. , 1995, Blood.

[38]  James M. Roberts,et al.  Inhibitors of mammalian G1 cyclin-dependent kinases. , 1995, Genes & development.

[39]  P. Goodfellow,et al.  Single missense mutation in the tyrosine kinase catalytic domain of the RET protooncogene is associated with multiple endocrine neoplasia type 2B. , 1994, Proceedings of the National Academy of Sciences of the United States of America.

[40]  C. Healey,et al.  Point mutation within the tyrosine kinase domain of the RET proto-oncogene in multiple endocrine neoplasia type 2B and related sporadic tumours. , 1994, Human molecular genetics.

[41]  R. Hofstra,et al.  A mutation in the RET proto-oncogene associated with multiple endocrine neoplasia type 2B and sporadic medullary thyroid carcinoma , 1994, Nature.

[42]  P. Goodfellow,et al.  Mutations in the RET proto-oncogene are associated with MEN 2A and FMTC. , 1993, Human molecular genetics.

[43]  B. Ponder,et al.  Germ-line mutations of the RET proto-oncogene in multiple endocrine neoplasia type 2A , 1993, Nature.

[44]  C. Mathew,et al.  Genetic events in tumour initiation and progression in multiple endocrine neoplasia type 2 , 1993, Genes, chromosomes & cancer.

[45]  D. Schaid,et al.  Loss of heterozygosity suggests multiple genetic alterations in pheochromocytomas and medullary thyroid carcinomas. , 1991, The Journal of clinical investigation.

[46]  Samaan Na,et al.  Deletion mapping on the distal third region of chromosome 1p in multiple endocrine neoplasia type IIA. , 1990 .

[47]  C. Mathew,et al.  Deletion of genes on chromosome 1 in endocrine neoplasia , 1987, Nature.

[48]  P. Pandolfi,et al.  p18 Ink4c and Pten constrain a positive regulatory loop between cell growth and cell cycle control. , 2006, Molecular and cellular biology.

[49]  V. Godfrey,et al.  CDK inhibitors p18 INK4c and p27 Kip1 mediate two separate pathways to collaboratively suppress pituitary tumorigenesis , 1998 .

[50]  R. Marmorstein,et al.  Crystal structure of the CDK4/6 inhibitory protein p18INK4c provides insights into ankyrin-like repeat structure/function and tumor-derived p16INK4 mutations , 1998, Nature Structural Biology.

[51]  L. Mulligan,et al.  Mutations of the RET proto‐oncogene in the multiple endocrine neoplasia type 2 syndromes, related sporadic tumours, and Hirschsprung disease , 1997, Human mutation.

[52]  C. Nguyen,et al.  Deletion mapping on the distal third region of chromosome 1p in multiple endocrine neoplasia type IIA. , 1990, Anticancer research.